BioMedWire Stocks

Armistice Capital LLC Cuts Stake in Shopify by 59%

Last week, a well-known hedge fund based in New York significantly reduced its stake in Shopify Inc. Shopify is a multinational, e-commerce company headquartered in Ontario, Canada. The company offers e-commerce solutions for micro, small and large businesses, allowing them to sell their services and products online without any hitches.

The hedge fund in question, Armistice Capital LLC, is a global value-oriented and event-driven hedge fund that focuses primarily on the healthcare and consumer sectors. Armistice recently filed a report with the Securities & Exchange Commission reducing its position in Shopify by 59%. It is reported that the institutional investor is left with 256,000 shares in the e-commerce company, having already sold 369,000 shares in 2020.

This news comes as a surprise to many experts in the industry, especially since Shopify experienced massive growth at the start of the pandemic as a result of a considerable increase in online shopping.

Despite Shopify showing promise as its profitability and popularity continues to grow, Armistice Capital has made the decision to reevaluate its investment strategy, with its recent move suggesting that its view of the e-commerce company’s potential for financial gain may have shifted.

Armistice has yet to clarify the factors that may have contributed to its change of heart with regard to Shopify. However, speculation points to increased competition from other companies as well as market volatility, with some arguing that this may discourage investors who saw potential in the e-commerce giant.

While it remains unclear whether this decision by Armistice Capital will cause ripple effects throughout the marketplace, the move to reduce its stake has conveyed a message of uncertainty when it comes to the future of the e-commerce industry.

This comes as another globally renowned institutional investment company, Baillie Gifford & Co, increases its stake in the company. During the fourth quarter alone, Baillie Gifford & Co. bought an additional 12.3% stake in Shopify, acquiring almost 8 million shares for a little more than $2.5 million. Additionally, Sand Capital Management LLC, Franklin Resources Inc. and Vanguard Group Inc. have also increased their position in the multinational e-commerce company in the last three quarters.

Furthermore, different research reports conducted by service providers and financial analysts such as the Royal Bank of Canada and Bloomberg.com also show investors’ bullish sentiments on Shopify’s price from now onwards.

Data from Jefferies Financial Group shows the company raised its price objective on Shopify’s shares to $65 from $44, while the Royal Bank of Canada also increased its price objective to $75 from $65.

A number of companies such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) have dipped a foot in the healthcare ecommerce space, and such significant interest could result in major innovations within that space during the coming years.

NOTE TO INVESTORS: The latest news and updates relating to NextPlat Corp. (NASDAQ: NXPL) are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease

UCLA researchers have developed a smart pen that can detect Parkinson’s during its early stages…

5 hours ago

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Clene Inc. reported new preclinical data on its drug candidate CNM-Au8 for Parkinson’s disease. The…

5 hours ago

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): When 15 Years of Data Creates Unassailable AI Advantage

Proprietary machine-learning reconstruction algorithm trained on 15 years of breast CT data positions IzoView to…

4 days ago

HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch

Company releases report updating status of proprietary 12-lead ECG synthesis software for arrhythmia assessment. Earlier…

4 days ago

Study Finds That Common Sweetener Could Compromise Cancer Treatment Effectiveness

Researchers at University of Pittsburg have found that patients who consume sucralose regularly have a…

4 days ago

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Exclusive CADx Patent Positions IzoView as First-Mover in AI-Enhanced Breast CT

Exclusive U.S. patent rights for computer-aided diagnosis (“CADx”) with breast CT secured through a global…

5 days ago